GH SEC Filings: 8-K, 10-Q, S-3 & 424B – Guardant Health

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 19, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 29, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 30, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Nov 5, 2026

8-K

Kevin Sayer Joins Guardant Health Board of Directors

Nov 3, 2026

8-K

Guardant Health Grants Performance-Based Stock Units to Co-CEOs

Nov 3, 2026

8-K

Guardant Health Reports Q2 2026 Financial Results and Increases Full-Year 2026 Revenue Guidance

Jul 30, 2026

8-K

Guardant Health, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 18, 2026

8-K

Guardant Health Reports Q1 2026 Financial Results and Increases Full-Year Revenue Guidance

May 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

FIXED PRICE OFFERING | Offering amount: $299,999,970 | Shares: 3,333,333 | Price: $90.000 | Bank: Goldman Sachs & Co. LLC, Jefferies, Leerink Partners, Guggenheim Securities

Nov 6, 2025

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $250,000,000 | Shares: 3,032,753 | Bank: Goldman Sachs & Co. LLC

Nov 4, 2025

424B5

Up to $400,000,000 Common Stock PROSPECTUS SUPPLEMENT Jefferies August 23, 2024

Aug 23, 2024

424B5

3,387,446 Shares of Common Stock

Dec 21, 2023

424B5

12,500,000 Shares

May 23, 2023

424B5

Common Stock

May 22, 2023

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

FMR LLC (Filed by)

Nov 5, 2026

MIGNONE ROBERTO (Reporting)

Oct 22, 2026

Hidalgo Medina Manuel (Reporting)

Oct 19, 2026

Tariq Musa (Reporting)

Oct 19, 2026

144

Form 144 - Report of proposed sale of securities

Oct 16, 2026

Azar Alex M II (Reporting)

Oct 15, 2026

Other

TYPE

HEADLINE

FILED AT

CT ORDER

Form CT ORDER - Confidential treatment order

Feb 8, 2022

EFFECT

Form EFFECT - Notice of Effectiveness

May 23, 2019

CORRESP

Form CORRESP - Correspondence

May 20, 2019

CORRESP

Form CORRESP - Correspondence

May 20, 2019

LETTER

Form UPLOAD - SEC-generated letter

May 15, 2019

LETTER

Form UPLOAD - SEC-generated letter

May 15, 2019

Guardant Health, Inc. GH · SEC Filings